Back to search

Article

Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 Trial

2021-06-11

Abstract excerpt

<h4>Background: </h4> In MONARCH 2, abemaciclib plus fulvestrant significantly improved median progression-free survival (PFS, 16.4 vs 9.3 months, hazard ratio [HR], 0.553) and overall survival (OS, 46.7 vs 37.3 months; HR, 0.757) compared with placebo plus fulvestrant in hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC) patients...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
25c9719a-a37d-5b4a-8d07-df2744f7c1a0
DOI
10.21203/rs.3.rs-601421/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 TrialDOI 10.21203/rs.3.rs-601421/v1
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.Semantic proximity
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.Semantic proximity
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.Semantic proximity
Clinical, pathological and molecular predictors of Fulvestrant long-term benefit in Hormone Receptor-positive / HER2 negative advanced breast cancerSemantic proximity
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.Semantic proximity
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.Semantic proximity
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.Semantic proximity
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.Semantic proximity
Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity
The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity
Select a neighboring publication to make it the new centre.